Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Master Transcription Regulators

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Single-nucleus profiling reveals a core disease signature and cell type-specific vulnerabilities in early Rett syndrome.

Science advances·2026

Same author

Astrocytic ACSBG1 depletion improves lipid-cytokine signaling and attenuates α-Synuclein pathology in a Parkinson's disease mouse model.

bioRxiv : the preprint server for biology·2026

Same author

Publisher Correction: Presymptomatic training mitigates functional deficits in a mouse model of Rett syndrome.

Nature·2026

Same author

Transcriptomic data and biomedical literature synergize in finding pharmacologic gene regulators.

bioRxiv : the preprint server for biology·2026

Same author

Modulating alternative splicing of <i>MECP2</i> is a potential therapeutic strategy for Rett syndrome.

Science translational medicine·2026

Same author

Unconstrained Plasticity Disrupts Memory Consolidation in a Mouse Model of Rett Syndrome.

bioRxiv : the preprint server for biology·2026

Same journal

Erratum for the Research Article "Detecting supramolecular organic nanoparticles during heat wave".

Science (New York, N.Y.)·2026

Same journal

Local signals, systemic decline.

Science (New York, N.Y.)·2026

Same journal

The mechanics of liver regeneration.

Science (New York, N.Y.)·2026

Same journal

Computing in a memory with physics.

Science (New York, N.Y.)·2026

Same journal

Retraction.

Science (New York, N.Y.)·2026

Same journal

Making time.

Science (New York, N.Y.)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants

An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants

Published on: May 22, 2020

Adult neural function requires MeCP2.

Christopher M McGraw¹, Rodney C Samaco, Huda Y Zoghbi

¹Program in Developmental Biology, Baylor College of Medicine, Houston, TX 77030, USA.

Science (New York, N.Y.)

|June 4, 2011

Summary

This summary is machine-generated.

Rett syndrome therapies require lifelong maintenance. Early methyl-CpG-binding protein 2 (MeCP2) function is crucial for adult neurological health, and its loss causes disease symptoms, even when deleted in adulthood.

More Related Videos

A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome

A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome

Published on: May 22, 2019

Methods for the Modulation and Analysis of NF-κB-dependent Adult Neurogenesis

Methods for the Modulation and Analysis of NF-κB-dependent Adult Neurogenesis

Published on: February 13, 2014

Related Experiment Videos

Last Updated: Jun 1, 2026

An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants

An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants

Published on: May 22, 2020

A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome

A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome

Published on: May 22, 2019

Methods for the Modulation and Analysis of NF-κB-dependent Adult Neurogenesis

Methods for the Modulation and Analysis of NF-κB-dependent Adult Neurogenesis

Published on: February 13, 2014

Area of Science:

Neuroscience
Epigenetics
Genetics

Background:

Rett syndrome (RTT) is a neurodevelopmental disorder linked to mutations in the MECP2 gene.
MeCP2 (methyl-CpG-binding protein 2) is an epigenetic regulator critical for neurological function.
The necessity of sustained MeCP2 activity beyond early development for RTT remains unclear.

Purpose of the Study:

To investigate the role of MeCP2 in adult neurological function in a mouse model of Rett syndrome.
To determine if early-life MeCP2 expression can confer lasting protection against RTT phenotypes.
To assess the therapeutic window for maintaining MeCP2 function in RTT.

Main Methods:

Utilized an inducible mouse model to delete the Mecp2 gene in adult animals.
Compared phenotypes of adult-onset Mecp2 deletion with germline knockout models.
Evaluated the persistence of MeCP2's functional effects after its deletion.

Main Results:

Deletion of Mecp2 in adult mice replicated the severe phenotype observed in germline knockouts.
This demonstrates an essential, ongoing role for MeCP2 in maintaining adult neurological function.
Unlike other early epigenetic programming, MeCP2's functional benefits diminished rapidly upon its deletion.

Conclusions:

Sustained MeCP2 activity is critical for ongoing neurological health, not just early development.
Therapeutic strategies for Rett syndrome must address the continuous need for MeCP2 function throughout life.
Early-life epigenetic modifications mediated by MeCP2 do not provide permanent protection.